BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

ConferenceGLIX1Positive

AI Analysis

Summary

BioLineRx and Hemispherian AS will present preclinical efficacy data and Phase 1/2a trial design for GLIX1 at the 21st EANO meeting in 2026. The presentation represents early-stage development progress in oncology.

Clinical Trial Data

Phase

1/2a

Outcome Details

Preclinical efficacy data and Phase 1/2a trial design presentation

Importance:4/10

Sentiment:

0.40

oncologyPhase 1/2aconference presentationpreclinical dataEANO 2026

Related Companies

$BLRX

Read the original article

Published by PR Newswire Clinical Trials on September 10, 2026 11:00 AM

Read Original